Rafarma Pharmaceuticals, Inc.
RAFA
Rank in Stocks
#32507
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that... Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Share Price
$0.0173
Last synced: 2026-11-09
Market Cap
$1.52M
Change (1 day)
50.43%
Change (1 year)
-50.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rafarma Pharmaceuticals, Inc. (RAFA)
Category
Healthcare
EPS for Rafarma Pharmaceuticals, Inc. (RAFA)
EPS as of June 2026 TTM: $0.00
According to Rafarma Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, equal to its 2024 EPS of 0.00.
EPS history for Rafarma Pharmaceuticals, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 33.33% |
| 2025 | 0.00 | 33.33% |
| 2024 | 0.00 | -3.23% |
| 2023 | 0.00 | -94.51% |
| 2022 | $0.06 | -56.54% |
| 2021 | $0.13 | -23.53% |
| 2020 | $0.17 | -170,100.00% |
| 2019 | 0.00 | -91.67% |
| 2018 | 0.00 | 500.00% |
| 2014 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 282,569.57% |
DE
|
|
| $6.08 | 264,143.48% |
DE
|
|
| $1.55 | 67,317.39% |
JP
|
|
| $3.66 | 159,030.43% |
CH
|
|
| $0.45 | 19,465.22% |
IL
|
Questions about Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS)?
Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) was 0.00, compared with 0.00 in 2024.
How has Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2020 ($0.17) and lowest in 2025 (0.00).
How does Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Rafarma Pharmaceuticals, Inc.'s earnings per share (EPS) ($0.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.